Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Fresh from the Pipeline
  • Published:

Decitabine

Nature Reviews Drug Discovery volume 5, pages 891–892 (2006)Cite this article

Abstract

Decitabine (Dacogen; MGI Pharma), a nucleoside analogue that inhibits DNA methylation, was approved by the US FDA for the treatment of myelodysplastic syndromes in May 2006.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: DNA methyltransferase inhibitors.

References

  1. Heaney, M. L. & Golde, D. W. Myelodysplasia. N. Engl. J. Med. 340, 1649–1660 (1999).

    Article  CAS  Google Scholar 

  2. Silverman, L. R. & Mufti, G. J. Methylation inhibitor therapy in the treatment of myelodysplastic syndrome. Nature Clin. Pract. Oncol. 2, S12–S23 (2005).

    Article  CAS  Google Scholar 

  3. Issa, J.-P. J., Kantarjian, H. M. & Kirkpatrick, P. Azacitidine. Nature Rev. Drug Discov. 4, 275–276 (2005).

    Article  CAS  Google Scholar 

  4. Baylin, S. B. DNA methylation and cancer. Nature Clin. Pract. Oncol. 2, S4–S11 (2005).

    Article  CAS  Google Scholar 

  5. Jones, P. A. & Taylor, S. M. Cellular differentiation, cytidine analogues and DNA methylation. Cell 20, 85–93 (1980).

    Article  CAS  Google Scholar 

  6. Charache, S. et al. Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta globin gene complex. Proc. Natl Acad. Sci. USA 80, 4842–4846 (1983).

    Article  CAS  Google Scholar 

  7. Daskalakis, M. et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza-2′-deoxycytidine (decitabine) treatment. Blood 100, 2957–2964 (2002).

    Article  CAS  Google Scholar 

  8. FDA labelling information [online], (2006).

  9. Kantarjian, H. et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a Phase III randomized study. Cancer 106, 1794–1803 (2006).

    Article  CAS  Google Scholar 

  10. Wijermans, P. et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956–962 (2000).

    Article  CAS  Google Scholar 

  11. List, A. et al. Efficacy of lenalidomide in myelodysplastic syndromes. N. Engl. J. Med. 352, 549–557 (2005).

    Article  CAS  Google Scholar 

  12. Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429–2440 (2002).

    Article  CAS  Google Scholar 

  13. Kornblith, A. B. et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 20, 2441–2452 (2002).

    Article  CAS  Google Scholar 

  14. Gore, S. D. et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 66, 6361–6369 (2006).

    Article  CAS  Google Scholar 

  15. Kantarjian, H. et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1 Aug 2006 (doi: blood-2006-05-021162v1).

  16. Garcia-Manero, G. et al. Phase I/II study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 1 Aug 2006 (doi: blood-2006-03-009142v1).

  17. Cameron, E. E. et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature Genet. 21, 103–107 (1999).

    Article  CAS  Google Scholar 

  18. Myelodysplastic Syndromes: Basic Explanations 1–19 (Aplastic Anemia & MDS International Foundation, Annapolis, Maryland, 2005).

  19. IMS Health, IMS MIDAS MAT (June 2006).

Download references

Author information

Authors and Affiliations

  1. the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, 1650 Orleans Street, Baltimore, 21231, Maryland, USA

    Steven D. Gore

  2. IMS Health, 7 Harewood Avenue, London, NW1 6JB, UK

    Carole Jones

  3. Nature Reviews Drug Discovery,

    Peter Kirkpatrick

Authors
  1. Steven D. Gore
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carole Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter Kirkpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gore, S., Jones, C. & Kirkpatrick, P. Decitabine. Nat Rev Drug Discov 5, 891–892 (2006). https://doi.org/10.1038/nrd2180

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2180

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing